HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Population pharmacokinetics of aripiprazole in healthy Korean subjects.

AbstractOBJECTIVE:
Aripiprazole is widely used to treat schizophrenia and bipolar disorder. This study aimed to develop a combined population pharmacokinetic model for aripiprazole in healthy Korean subjects and to identify the significant covariates in the pharmacokinetic variability of aripiprazole.
METHODS:
Aripiprazole plasma concentrations and demographic data were collected retrospectively from previous bioequivalence studies that were conducted in Chonbuk National University Hospital. Informed consent was obtained from subjects for cytochrome P450 (CYP) genotyping. The population pharmacokinetic parameters of aripiprazole were estimated using nonlinear mixed-effect modeling with first-order conditional estimation with interaction method. The effects of age, sex, weight, height, and CYP genotype were assessed as covariates.
RESULTS:
A total of 1,508 samples from 88 subjects in three bioequivalence studies were collected. The two-compartment model was adopted, and the final population model showed that the CYP2D6 genotype polymorphism, height and weight significantly affect aripiprazole disposition. The bootstrap and visual predictive check results were evaluated, showing that the accuracy of the pharmacokinetic model was acceptable.
CONCLUSIONS:
A population pharmacokinetic model of aripiprazole was developed for Korean subjects. CYP2D6 genotype polymorphism, weight, and height were included as significant factors affecting aripiprazole disposition. The population pharmacokinetic parameters of aripiprazole estimated in the present study may be useful for individualizing clinical dosages and for studying the concentration-effect relationship of the drug.
AuthorsJi-Young Jeon, Soo-Wan Chae, Min-Gul Kim
JournalInternational journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 54 Issue 4 Pg. 293-304 (Apr 2016) ISSN: 0946-1965 [Print] Germany
PMID26902506 (Publication Type: Journal Article)
Chemical References
  • Antipsychotic Agents
  • Aripiprazole
  • Cytochrome P-450 CYP2D6
Topics
  • Antipsychotic Agents (pharmacokinetics)
  • Aripiprazole (pharmacokinetics)
  • Cytochrome P-450 CYP2D6 (genetics)
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Models, Biological
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: